Quantitative [F]PSMA-1007 PET in Treatment Response Monitoring of Brain Metastases from Non-small Cell Lung Cancer.
OpenAlex 토픽 ·
Brain Metastases and Treatment
Lung Cancer Research Studies
Prostate Cancer Treatment and Research
[PURPOSE] Prostate-specific membrane antigen (PSMA) is expressed in several solid tumours, including brain metastases (BMs) from lung cancer.
APA
Elisabeth Kirkeby Lysvik, Andreas Julius Tulipan, et al. (2026). Quantitative [F]PSMA-1007 PET in Treatment Response Monitoring of Brain Metastases from Non-small Cell Lung Cancer.. Molecular imaging and biology. https://doi.org/10.1007/s11307-026-02104-w
MLA
Elisabeth Kirkeby Lysvik, et al.. "Quantitative [F]PSMA-1007 PET in Treatment Response Monitoring of Brain Metastases from Non-small Cell Lung Cancer.." Molecular imaging and biology, 2026.
PMID
42026421
Abstract
[PURPOSE] Prostate-specific membrane antigen (PSMA) is expressed in several solid tumours, including brain metastases (BMs) from lung cancer. We investigated quantitative [F]PSMA-1007 uptake and treatment response in BMs of patients with non-small cell lung cancer (NSCLC).
[PROCEDURES] Eleven patients with BM of NSCLC underwent 95-min dual-time-point dynamic [F]PSMA-1007 PET/CT and a whole-body static scan before and after stereotactic radiosurgery (SRS) with a median dose of 20 Gy (range: 8-25 Gy) given in a median of 1 fraction (range: 1-3). Seven patients completed both exams. Image-derived input functions were extracted from the internal carotid arteries, and pharmacokinetic analysis using Patlak modelling yielded the influx constant (K). Standardised uptake value (SUV), biological tumour volume (BTV) and tumour heterogeneity using the coefficient of variance (CoV) were assessed.
[RESULTS] [F]PSMA-1007 PET showed uptake in the first exam in BMs and primary lung tumour in all patients. Significant inter-patient and intra-lesion heterogeneity in tracer uptake was observed in BMs with median Ki of 0.005 ml/ccm/min (range: 0.003-0.018 ml/ccm/min), SUV of 4.2 g/ml (range: 0.4-34.4 g/ml), CoV of 0.36 (range 0.06-0.85) and BTV of 2.35 ml (range 0.03-22.29 ml). After SRS, reductions in K (37%), SUV (50%), CoV (24%) and BTV (71%) were noted. Median SUV in the lungs were 6.1 g/ml (range: 3.2-13.6 g/ml) at the initial exam and 6.3 g/ml (range: 3.8-11.8 g/ml) at the second exam.
[CONCLUSION] [F]PSMA-1007 PET is a promising diagnostic tool for BMs from NSCLC. The uptake and heterogeneity, along with the marked reduction post-therapy, highlights its potential for monitoring treatment response.
[TRIAL REGISTRATION] Clinicaltrials.gov, NCT03951142. Registered 5 October 2019, https://clinicaltrials.gov/ct2/show/NCT03951142 . EudraCT no 2018-003229-27. Registered 26 February 2019, https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003229-27/NO .
[PROCEDURES] Eleven patients with BM of NSCLC underwent 95-min dual-time-point dynamic [F]PSMA-1007 PET/CT and a whole-body static scan before and after stereotactic radiosurgery (SRS) with a median dose of 20 Gy (range: 8-25 Gy) given in a median of 1 fraction (range: 1-3). Seven patients completed both exams. Image-derived input functions were extracted from the internal carotid arteries, and pharmacokinetic analysis using Patlak modelling yielded the influx constant (K). Standardised uptake value (SUV), biological tumour volume (BTV) and tumour heterogeneity using the coefficient of variance (CoV) were assessed.
[RESULTS] [F]PSMA-1007 PET showed uptake in the first exam in BMs and primary lung tumour in all patients. Significant inter-patient and intra-lesion heterogeneity in tracer uptake was observed in BMs with median Ki of 0.005 ml/ccm/min (range: 0.003-0.018 ml/ccm/min), SUV of 4.2 g/ml (range: 0.4-34.4 g/ml), CoV of 0.36 (range 0.06-0.85) and BTV of 2.35 ml (range 0.03-22.29 ml). After SRS, reductions in K (37%), SUV (50%), CoV (24%) and BTV (71%) were noted. Median SUV in the lungs were 6.1 g/ml (range: 3.2-13.6 g/ml) at the initial exam and 6.3 g/ml (range: 3.8-11.8 g/ml) at the second exam.
[CONCLUSION] [F]PSMA-1007 PET is a promising diagnostic tool for BMs from NSCLC. The uptake and heterogeneity, along with the marked reduction post-therapy, highlights its potential for monitoring treatment response.
[TRIAL REGISTRATION] Clinicaltrials.gov, NCT03951142. Registered 5 October 2019, https://clinicaltrials.gov/ct2/show/NCT03951142 . EudraCT no 2018-003229-27. Registered 26 February 2019, https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003229-27/NO .